These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 14522223)

  • 1. Manufacturing uncertainty: adverse effects of drug development for women.
    Peppin P
    Int J Law Psychiatry; 2003; 26(5):515-32. PubMed ID: 14522223
    [No Abstract]   [Full Text] [Related]  

  • 2. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 3. Epidemiology of medications use in pregnancy.
    Ayad M; Costantine MM
    Semin Perinatol; 2015 Nov; 39(7):508-11. PubMed ID: 26358804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

  • 5. Commentary by a child psychiatrist in industry on the assessment of drug safety.
    Allen AJ
    J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):288-91. PubMed ID: 17630860
    [No Abstract]   [Full Text] [Related]  

  • 6. Minimum acceptable requirements for introduction and marketing of drugs.
    Lasagna L
    Drugs; 1974; 7(6):409-13. PubMed ID: 4422210
    [No Abstract]   [Full Text] [Related]  

  • 7. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 8. Schroeder Lecture. Worst pills, best pills.
    Wolfe SM
    Health Matrix Clevel; 2006; 16(2):785-96. PubMed ID: 16948255
    [No Abstract]   [Full Text] [Related]  

  • 9. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.
    Cheng CM; Shin J; Guglielmo BJ
    JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107
    [No Abstract]   [Full Text] [Related]  

  • 10. Issues in bringing new drugs to the market.
    Ammann AJ
    Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329171
    [No Abstract]   [Full Text] [Related]  

  • 11. Raising the safety bar--the FDA's coxib meeting.
    Okie S
    N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
    [No Abstract]   [Full Text] [Related]  

  • 12. Indication creep: physician beware.
    Hébert PC; Stanbrook M
    CMAJ; 2007 Sep; 177(7):697, 699. PubMed ID: 17823137
    [No Abstract]   [Full Text] [Related]  

  • 13. Safer use of medications through risk evaluation and mitigation strategies: Academy perspectives.
    Hennessy KF; Williams KG; Bongero D
    J Am Pharm Assoc (2003); 2010; 50(5):556-62. PubMed ID: 20833611
    [No Abstract]   [Full Text] [Related]  

  • 14. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.
    Qato DM; Alexander GC
    JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303
    [No Abstract]   [Full Text] [Related]  

  • 15. Drugs in pregnancy--the issues for 2010.
    Davis DB
    J Popul Ther Clin Pharmacol; 2010; 17(3):e332-5. PubMed ID: 21041865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-examining our approach to the approval and use of new drugs.
    Lee SK
    CMAJ; 2006 Jun; 174(13):1855. PubMed ID: 16785460
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 18. Striking the right balance.
    Nat Rev Drug Discov; 2006 Nov; 5(11):879. PubMed ID: 17117516
    [No Abstract]   [Full Text] [Related]  

  • 19. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.
    Psaty BM; Meslin EM; Breckenridge A
    JAMA; 2012 Jun; 307(23):2491-2. PubMed ID: 22563032
    [No Abstract]   [Full Text] [Related]  

  • 20. News from the Society for Women's Health Research: FDA doing poor job of monitoring drugs for sex differences.
    Greenberger P
    J Womens Health Gend Based Med; 2001 Nov; 10(9):829-30. PubMed ID: 11747675
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.